​Cayman offers a comprehensive portfolio of high‑purity lipids and conjugation‑ready components designed to support both passive and active targeting strategies in lipid nanoparticle (LNP) formulation. From ionizable cationic lipids to PEGylated and ligand‑modified components, our solutions help researchers optimize LNP stability, biodistribution, and targeted delivery for advanced therapeutic applications.